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http://dx.doi.org/10.1016/j.ccell.2014.09.014SUMMARYNeuroblastoma is an embryonal tumor of the sympathetic nervous system and themost common extracranial
tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differ-
entially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA
neuroblastoma associated transcript-1 (NBAT-1) as a biomarker significantly predicting clinical outcome
of neuroblastoma. CpG methylation and a high-risk neuroblastoma associated SNP on chromosome 6p22
functionally contribute to NBAT-1 differential expression. Loss of NBAT-1 increases cellular proliferation
and invasion. It controls these processes via epigenetic silencing of target genes. NBAT-1 loss affects
neuronal differentiation through activation of the neuronal-specific transcription factor NRSF/REST. Thus,
loss of NBAT-1 contributes to aggressive neuroblastoma by increasing proliferation and impairing differen-
tiation of neuronal precursors.INTRODUCTION
Neuroblastoma is one of the most common extracranial solid tu-
mors in children. It is thought to arise from improper differentia-Significance
Despite recent progress in diagnosis and treatment of neurob
roblastoma is still less than 50%. This warrants better biologic
form the basis for improved prognostication, management, a
study, we identified NBAT-1 lncRNA as a prognostic biomar
Lower expression of NBAT-1 significantly correlates with poor
patients. NBAT-1 controls tumor progression by epigenetically
ation of undifferentiated tumor cells. Therefore, NBAT-1 and its
opment and options for high-risk neuroblastoma treatment.
722 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Inction of neuronal precursor cells of the sympathetic nervous sys-
tem. These tumorsmost commonly occur in the adrenal medulla,
but also in sympathetic ganglia of the abdominal organs and of
the sympathetic trunk (Brodeur, 2003; Kamijo and Nakagawara,lastoma, survival for children with high-risk metastatic neu-
al understanding and drug target identification, which could
nd treatment for high-risk neuroblastoma patients. In this
ker and potential drug target for therapeutic interventions.
overall and event free survival probability of neuroblastoma
repressing tumor inducing genes and promoting differenti-
target genes may serve as potential targets for drug devel-
.
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Long Noncoding RNAs in Neuroblastoma Pathogenesis2012). Features like age of the patient at diagnosis, stage of the
disease, and nonrandom chromosomal aberrations are well-es-
tablished parameters for stratification of risk and treatment as
well as for predicting the disease outcome in patients (Cohn
et al., 2009; Monclair et al., 2009). Neuroblastoma patients with
nonrandom chromosomal alterations MNA (MYCN amplifica-
tion)/1p (shorter arm of the chromosome 1) deletion/17q (longer
arm of the chromosome 17) gain (seen in 20% of patients) or 11q
deletion (11q-) /17q gain (seen in 30% of patients) are often as-
sociated with high-risk tumors and an unfavorable outcome. Tu-
mors with hyperdiploidy and numerical aberrations of whole
chromosomes are associated with low-risk clinical stages and
are prognostically favorable (Brodeur et al., 1984; Care´n et al.,
2010; Caron, 1995; Guo et al., 1999; Lastowska et al., 2001; Spitz
et al., 2003). In addition to nonrandom chromosomal alterations,
some neuroblastomas (7%) display recurrent point mutations in
the tyrosine kinase domain of the anaplastic lymphoma kinase
gene (Care´n et al., 2008a; Chen et al., 2008; George et al.,
2008; Janoueix-Lerosey et al., 2008; Mosse´ et al., 2008; Wang
et al., 2012a), and genes that take part in neuritogenesis (Mole-
naar et al., 2012). Recent genome-wide association studies on
large patient cohorts have also uncovered clusters of germline
SNPs, in six genomic regions. Three SNPs from these clusters
map to 6p22 region, and one of the SNPs rs6939340 is located
in intronic region of a lncRNA LOC729177. Neuroblastoma pa-
tients with homozygous risk G allele at the SNP: rs6939340 are
likely to have metastatic disease and poor event free survival
(Diskin et al., 2012; Maris et al., 2008). Besides nonrandom
somatic genomic alterations and germline SNPs, array based
gene expression profiles have also shown associations with clin-
ical subtypes (Fischer et al., 2008).
In the light of current transcriptomic studies, it is evident that
the major part of the transcribed genome is noncoding. The
RNA from the nonprotein coding genome is mainly comprised
of small ncRNAs, long noncoding RNAs (lncRNAs), and unanno-
tated intergenic transcribed regions. LncRNAs have been impli-
cated in diverse cellular processes with distinct regulatory roles
(Kanduri, 2011; Whitehead et al., 2009). Several lncRNAs, for
example PCAT-1, MALAT1, HOTAIR, and ANRIL, have been
implicated in tumorigenesis (Batista and Chang, 2013; Prensner
and Chinnaiyan, 2011; Prensner et al., 2011; Spizzo et al., 2012;
Taft et al., 2010). Thus, studying and evaluating the expression of
these nontranslated regions could be of profound value in terms
of disease characterization. We therefore set out to identify
lncRNA-based biomarkers that could be used in neuroblastoma
risk assessment and therapy.
RESULTS
Identification of Transcripts Specific to Distinct
Subtypes of Neuroblastomas
In this study, we performed high-throughput transcriptomic
profiling of 15 neuroblastoma tumors, three of which were low-
risk, whereas of the remaining 12, six each were of the MNA or
11q high-risk subtypes (Care´n et al., 2010). An unsupervised
clustering analysis on all transcripts detected significant differ-
ences in expression signatures between low- and high-risk tu-
mors, as well as between the two subtypes of high-risk tumors
(Figures 1A and 1B and Figure S1 available online), indicatingCanthat each neuroblastoma subtype carries unique gene expres-
sion signatures. We analyzed relative expression of protein cod-
ing, annotated and nonannotated lncRNAs by considering the
following comparisons of neuroblastoma tumors: low-risk versus
11q-, low-risk versus MNA, low-risk versus high-risk subtypes,
and 11q- versus MNA. These comparisons revealed several
differentially expressed transcripts (false discovery rate [FDR] <
0.1) (Figures 1C and 1D). We found a significant overlap for
protein coding genes between our analysis and the publishedmi-
croarray data set based on expression profile of 88 primary neu-
roblastoma tumors (R2 database http://r2.amc.nl) (Table S1). We
performed pathway analysis on differentially expressed protein
coding genes and found eight low-risk specific, 25 11q- specific,
and fiveMNA specific pathwayswith significant p values from the
comparisons between the three subtypes as shown in Figures 1A
and S1; Table S2. Mutational screening of genes differentially
expressed in this study showed that 27.4% (194/707) carried so-
matically acquired SNP or insertion and deletion variations pre-
dicted to result in nonsilent changes of coding regions, either in
our exome sequencing study or previously published neuroblas-
toma (NBL) sets of 13 and 349 tumors, respectively, (Molenaar
et al., 2012; Pugh et al., 2013; Sausen et al., 2013) in comparison
to 19.3% (3,787/19,638) of nondifferentially expressed genes. Of
the 707 differentially expressed genes, 11 genes (1.56%) (ALK,
MUC4, AHNAK2, AHNAK, DOCK8, FBN2, HSPG2, MYCN,
TNC, KIAA0319, and ODZ4) showed a mutation frequency
>1%with most recurrent mutations in ALK, concordant with pre-
vious studies, whereas 61 genes (0.31%) of the nondifferentially
expressed showedmutation frequency >1%with most recurrent
mutations inMUC16 (6.6%) and TTN (5.8%) (Table S3). However,
when we applied the MutSigCV v1.3 algorithm (Lawrence et al.,
2013) for all NBL sets, only the differentially expressed ALK
and the nondifferentially expressed ZNF717 were found to be
significantly mutated. Since the MutSigCV algorithm was devel-
oped against tumors with high frequency of mutations, functional
significance of rare mutations identified in this study remains to
be investigated in pediatric tumors, which are known to harbor
few somatic mutations.
The Expression Profile of Nonannotated Long
Noncoding RNAs Distinguishes between Low-Risk
and High-Risk Neuroblastoma
Differential expression analysis of lncRNAs between low- and
high-risk neuroblastomas revealed 24 nonannotated lncRNAs
(named as CUFF 1–24) (Figure S2A). As can be seen in the heat-
map (Figure 2A), the expression profiles of these nonannotated
lncRNAs clearly distinguish these two subtypes of tumors. The
relative expression of four of these transcripts is depicted in
box plots (Figure S2B). We validated their differential expression
in an independent cohort of 23 primary neuroblastoma tumors
representing low- and high-risk subtypes (Figure 2B). Interest-
ingly, many of these transcripts (9 of the 24) map to the chromo-
some 6q arm and show significant overexpression in high-risk
neuroblastomas compared to the low-risk subset (Figure S2C).
The Array comparative genomic hybridization (CGH) profiles of
the sequenced tumors did not show any genomic alterations at
these transcribed regions.
As lncRNAs are known to be expressed at lower levels in com-
parison to protein coding transcripts, many lncRNAs tend to filtercer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Inc. 723
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Figure 1. Differential Expression of Transcripts among Three Subtypes of Neuroblastomas
(A and B) Clustergrams (hierarchical clustering) representing the clustering and expression differences among the compared subtypes. Data is represented as
euclidean distance metric.
(C) List of differentially expressed transcripts (coding and noncoding) between the four different comparisons among the subtypes of sequenced neuroblas-
tomas.
(D) Pie chart depicting the percentage of different classes of transcripts differentially expressed between low- and high-risk tumors.
See also Figure S1 and Tables S1, S2, and S3.
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sensitivity for detecting differentially expressed lncRNAs, we
repeated the analyses exclusively on the lncRNA subset. These
analyses revealed 325 and 130 differentially expressed lncRNAs
between low-risk versus MNA tumors, and low-risk versus 11q-
tumors, respectively (Figures S2D and S2E; Table S4). We next
investigated whether any of the differentially expressed lncRNAs
from low- versus high-risk comparisons map to the character-
istic chromosomal abnormalities. We identified a 2 kilobases
(kb) lncRNA; mapping to the coamplified region located 293 kb
from the MYCN locus (Care´n et al., 2008b; Schwab, 1998).
Similar to MYCN, this lncRNA is overexpressed in MNA tumors
as compared to the sequenced low-risk and 11q-tumors (Fig-
ures 2C, 2D, S2F, and S2G). We observed a similar overexpres-
sion of the lncRNA in an independent set of five MNA tumors
compared to the low-risk and 11q-tumors (Figure S2G). The
hemizygous deletion of the 11q23 arm is another well-known
genomic aberration observed in case of non-MNA aggressive tu-
mors (Guo et al., 1999). We detected a lncRNA with significant
differential expression mapping to the deleted 11q23 region,724 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Incshowing lower expression in the 11q-tumors compared to the
low-risk tumors (Figures 2E, S2H, and S2I). Deletions in the 1p
arm are also known to be associated with aggressive neuroblas-
tomas. We identified five additional lncRNAs at the proximal end
of the 1p arm with low expression in MNA tumors compared to
11q- and low-risk tumors (Figure 2F). So we are able to provide
a putative list of differentially expressed nonannotated and anno-
tated lncRNAs that map to genomic regions that are prone to al-
terations in high-risk aggressive neuroblastoma tumors.
Neuroblastoma Associated Transcript-1 Is a Potential
Marker for Risk Assessment in Neuroblastoma
Our analyses on MNA and low-risk tumors revealed LOC729177
(GENCODE annotation, also referred to as CASC14) lncRNA as
one of the top ranked candidates with a significant p value (Table
S5; p = 0.0012). This transcript also appears as a differentially ex-
pressed candidate between low- and high-risk tumors (p =
0.002); it is expressed at low level in high-risk tumors compared
to low-risk tumors. Because the lncRNA harbors the high-risk
associated SNP: rs6939340 in its intron, we were interested in.
A B
C D
E F
(legend on next page)
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LOC729177 and the role of LOC729177 in neuroblastoma
pathogenesis.
Due to its association with neuroblastoma prognosis, we
named this RNA as neuroblastoma associated transcript 1
(NBAT-1). Using the codon substitutionmatrix andCodingPoten-
tial Assessment Tool (CPAT), as well as a comparison with known
protein sequences (Swiss-prot), we have evidence thatNBAT-1 is
a noncoding transcript (Figures S3A and S3B) (Wang et al., 2013).
The PhastCons score (Pollard et al., 2010) demonstrates that
some regions of NBAT-1 are similar across mammalian species,
indicating a possible evolutionarily conserved function (Fig-
ure S3C). It has tissue specific expression, mainly in the brain,
breast, and ovary (Figure S3D). Consistent with our sequencing
data; we observed a significantly lower expression of the
NBAT-1 in high-risk tumors compared to the non high-risk tumors
when analyzed in a clinical cohort comprising 93 neuroblastoma
patients (Figure 3A). We further validated NBAT-1 differential
expression in RNA sequencing data obtained from an indepen-
dent clinical cohort of 498 neuroblastomas (Figures 3B, 3C,
S3E, and S3F). Analysis of the prognostic value of NBAT-1 indi-
cated that patientswith highNBAT-1 expressionwere associated
with good prognosis (5 year overall survival [OS] of 0.86 ± 0.02,
and 5 year event free survival [EFS] 0.74 ± 0.03) as compared
to patients with low NBAT-1 expression (5 year OS of 0.66 ±
0.04, and 5 year EFS of 0.44 ± 0.04) (Figures 3D–3F and S3G).
Furthermore, the waterfall plot for ordered NBAT-1 expression
across all analyzed tumors with patient outcome corroborates
the findings from the survival analysis (Figures 3G and S3H).
Importantly, the multivariate Cox regression analysis on the
independent clinical cohort (n = 498, hazard ratio = 0.839, and
p = 0.038) suggests that NBAT-1 may act as an independent
prognostic marker in predicting event free survival (Figure 3H).
In addition, NBAT-1 could give prognostic information for chil-
dren with both MNA+ and MNA- tumors (Figures S3I–S3L). This
indicates that NBAT-1 expression is a significant independent
prognostic factor that could serve as an additional prognostic
marker for risk assessment in neuroblastoma patients.
We next sought to address the functional link between the
high-risk neuroblastoma associated SNP: rs6939340 and
NBAT-1 expression in primary tumors. We sequenced genomic
DNA over the SNP from 51 high-risk primary tumors used in the
quantitative reverse transcription (qRT)-PCR validation. High-
risk tumors with either A/G or A/A genotype had higher expres-
sion in comparison to tumors with G/G genotype (p = 0.03)
(Figures 4A and S4A). Thus, G/G genotype might be associatedFigure 2. Nonannotated Long Noncoding RNAs Are Differentially Expr
(A) Heatmap depicting the expression differences of nonannotated transcripts (C
(B) qRT-PCR validation of four differentially expressed CUFFs in an independen
corresponding GAPDH levels, and the normalized values are presented as boxp
presented as obtained from student’s t test (two tailed and unequal variance).
(C) Representative CGH Array profile of an amplified region containingMYCN on
the MYCN gene.
(D) Normalized read counts (reads per kb of transcript per million reads mapped
expression between the three subtypes.
(E) Genomic region on chromosome arm 11q showing lncRNA AP000997.2, diffe
(F) P arm of the chromosome 1 depicting the differentially expressed noncoding
expression levels (RPKM) of these transcripts between the three subtypes.
For (B), values represent mean ±SD. *p < 0.05. See also Figure S2 and Tables S
726 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Incwith lower NBAT-1 expression in high-risk tumors. We next gen-
otyped the SNP and analyzed the NBAT-1 expression in six neu-
roblastoma cell lines (Figure 4B). The SK-N-FI cell line with a G/G
genotype showed lower NBAT-1 expression compared to the
SH-SY5Y cell line with an A/A genotype. In addition, fragments
carrying the SNP generatedmore luciferase activity in PGL3 pro-
moter vectors, with an A/A genotype showing more luciferase
activity than the G/G genotype, indicating that the region span-
ning the SNP might be a putative enhancer element (Figure 4C).
In addition, higher order regulatory interactions between the SNP
and NBAT-1 promoter were detected in a chromosome confor-
mation capture (3C) experiment and in RNA polymerase II chro-
matin interaction analysis by paired-end tags (PolII ChIA-PET)
using the ENCODE data set in MCF7 cells (Li et al., 2012) (Fig-
ure 4D). The SNP region also carries characteristic enhancer-
specific marks (Figure 4E). The enrichment of enhancer specific
marks and 3C interaction was significantly lower in G/G as
compared to the A/A genotype (Figures 4D and 4E).
We next investigated additional factors that contribute toward
differential NBAT-1 expression between low- and high-risk neu-
roblastoma patients by analyzing DNA methylation at CpG
nucleotide sites flanking the NBAT-1 promoter using pyrose-
quencing. We found that five CpGs flanking the NBAT-1 pro-
moter were significantly hypermethylated in high-risk patients,
with lower NBAT-1 expression; whereas the CpGs were hypo-
methylated in low-risk patients with higher NBAT-1 expression
(Figures 4F and S4B–S4F). In addition, significant activation of
the NBAT-1 expression was detected in SK-N-AS cells upon
treatment with DNA demethylating agent 5-Aza-20-deoxycyti-
dine (DAC). These observations together suggest that DNA
methylation plays a functional role in the inactivation of the
NBAT-1 promoter in high-risk patients (Figure 4G).
Neuroblastoma Associated Transcript-1 Harbors Tumor
Suppressor Properties
Since the lower expression of NBAT-1 is correlated with aggres-
siveness in neuroblastoma patient tumors, we investigated the
effect of downregulation of NBAT-1 on the SH-SY5Y cells.
Depletion of NBAT-1 using two siRNAs (si-A and si-C) in the
SH-SY5Y cell line resulted in a significant increase in the number
of viable cells compared to the cells transfected with control
siRNA (Figures 5A and S5A). In addition, we generated a SH-
SY5Y cell line stably transduced with lentivirus carrying NBAT-
1 specific short hairpin RNA (NBAT1-sh) that displays a 70% to
80% downregulation of NBAT-1 compared to the cell line stably
transduced with lentivirus containing a scrambled short hairpinessed between Low- and High-Risk Tumors
UFF.1–24) between low- and high-risk tumors.
t cohort of neuroblastoma tumors. The expression levels were normalized to
lots where n represents the number of primary tumors used. The p values are
chromosome 2. The lncRNA CUFF.121734 is shown as coamplified along with
[RPKM] from sequencing) ofMYCN and CUFF.121734 show the differences in
rentially expressed between low-risk and 11q- tumors.
transcripts between the three subtypes. Bar graphs showing the normalized
4 and S5.
.
A B C
D E
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H
(legend on next page)
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Long Noncoding RNAs in Neuroblastoma PathogenesisRNA (Cntrl-sh) (data not shown). TheNBAT-1 shRNA transduced
SH-SY5Y cell line also showed a similar increase in the number
of viable cells, further confirming the antiproliferative activity of
NBAT-1 (Figure S5B). Suppression of NBAT-1 expression also
led to increased invasiveness of SH-SY5Y cells (Figure 5B).
Consistent with its antiproliferative property, we observed a
significant increase in the growth rate of NBAT-1 depleted xeno-
grafts (Figures 5C–5E). Hematoxylin and eosin staining of xeno-
graft sections of the NBAT1-sh and Cntrl-sh xenografts did not
reveal any gross morphological abnormalities (Figure 5F). How-
ever, using Ki67, a marker for cell proliferation, we observed
a significant increase in the number of replicating cells in
NBAT-1 depleted xenografts as compared to control xenografts
(Figures 5F and 5G). Together, these findings indicate that
NBAT-1 harbors tumor suppressor properties.
In order to identify the putative targets of NBAT-1 and to un-
derstand its inhibitory role in tumorigenesis, we sequenced the
total RNA from NBAT1-sh cells along with Cntrl-sh cells. There
were 1,348 (987 upregulated and 361 downregulated) protein-
coding genes (2-fold expression difference, FDR of < 0.05) that
showed differential expression upon NBAT-1 downregulation
(Figures S5C and S5D; Table S6). Importantly, the neighboring
transcript LINC00340 (CASC15) was not significantly affected
uponNBAT-1’s downregulation (data not shown). Gene ontology
analysis of the differentially expressed genes showed significant
enrichment for biological processes such as cell differentiation,
cell migration, and cell proliferation, along with neuronal
processes; nervous system development, neurogenesis, and
neuron differentiation (FDR < 0.05) (Figure 5H). Given that
abnormal cell proliferation and migration are among the impor-
tant contributing factors underlying tumor initiation and progres-
sion, we addressed plausible mechanisms by which NBAT-1
controls these biological processes. We noted that 49 (out of
335 genes; 15%) cell proliferation-specific genes and 57 genes
implicated in cell migration (121 genes; 47%) were among the
1,348 differentially expressed NBAT-1 target genes (Figures 5I
and 5J; Table S6). Differential expression of some of the key
target genes was validated upon NBAT-1 downregulation using
sh-RNA and two siRNAs (si-A and si-C) (Figures 5K and S5E),
including VCAN, SOX9, and OSMR, which are reported to be
overexpressed in a wide range of tumors (Cheon et al., 2014;
Kopp et al., 2012; Matheu et al., 2012; West et al., 2012; Yeung
et al., 2013). Interestingly, when the gene expression changes af-
ter NBAT-1 downregulation were compared with the R2 data set
(comprising differential expression of protein coding genes be-
tween low- and high-risk tumors), 45 common candidate genes
were found to have similar expression profiles, including VCAN
and SOX9 (with a p < 0.05) (Figure 5L).Figure 3. Neuroblastoma Associated Transcript-1 Long Noncoding RN
(A) qRT-PCR showing differential expression of NBAT-1 in 93 primary neurobla
normalization to GAPDH. ‘‘n’’ represents the number of primary tumors used. Th
(B and C) RNA sequencing showing differential expression of NBAT-1 in 498 tumo
System stage. The p values were obtained from Mann-whitney (B) or Dunn’s mu
(D–F) Kaplan-Meier curves indicating OS (D and E) and EFS (F) of patients in coho
Cox) test. Numbers in bracket represent the number of patients in the respective
(G) Waterfall plot of normalized log-transformed expression values ofNBAT-1 per
colors (alive with disease [AWD], dead of disease [DOD], no evidence of disease
(H) Multivariate Cox regression analysis investigating the independent prognostic
For (A)–(C), values represent mean ±SD. *p < 0.05, **p < 0.01, and ***p < 0.001.
728 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier IncTo address the significance of these cancer-related genes in
neuroblastoma, they were downregulated in NBAT1-sh cells us-
ing siRNAs (Figures S5F–S5H). As can be seen in Figure 5M,
downregulation of SOX9 and OSMR, but not VCAN affected
the proliferation potential of the NBAT1-sh cells. Interestingly,
downregulation of VCAN, SOX9, and OSMR also affected the
invasive capacity of NBAT1-sh cells (Figure 5N). These results,
taken together, suggest that higher expression of SOX9,
VCAN, and OSMR may contribute to tumor progression in
high-risk neuroblastoma patients.
To further understand the functional role of NBAT-1 in tumor
suppression and invasion, we have ectopically expressed NBAT-
1 in the neuroblastoma cell lines SK-N-AS and SK-N-BE(2), repre-
senting the two high-risk neuroblastoma subsets 11q- and MNA,
respectively (Care´n et al., 2010). NBAT-1 overexpression resulted
in decreased cell proliferation and invasion (Figures S5I–S5P),
further corroborating its functional role in tumor progression. Inter-
estingly, we observed consistent downregulation of SOX9 and
VCAN in bothcell lines, indicating thatNBAT-1mayexecute tumor
suppression via repressing SOX9 and VCAN genes.
We next sought to understand the mechanisms by which
NBAT-1 represses genes involved in tumor progression. To
this end, RNA immunoprecipiation assay (RIP) demonstrated
an interaction between NBAT-1 and PRC2 complex member
EZH2 (Figure 6A). To further understand the functional connec-
tion betweenNBAT-1 and EZH2, total RNA from theEZH2 down-
regulated SHSY-5Y cells was sequenced and investigated to
see if there is any functional overlap between the expression
changes seen in EZH2 and NBAT-1 downregulated cells (Table
S7). These two data sets showed significant overlap (r = 0.67)
(Figures 6B and 6C). Interestingly, a large majority of the overlap-
ped genes were also enriched with H3K27me3 modification
(Egan et al., 2013) (Figure 6C; Table S7). Genes implicated in
cell proliferation and cell migration were upregulated in both
NBAT-1 and EZH2 downregulated cells (Figures 5K, S5Q, and
S5R). H3K27me3modification at the promoters of some of these
genes was analyzed upon NBAT-1 downregulation using chro-
matin immunoprecipitation (ChIP)-qPCR (Figures 6D and 6E).
Loss of H3K27me3 modification was observed at the promoter
regions in NBAT-sh cells, indicating that theNBAT-1/EZH2 func-
tional interaction suppresses its target genes implicated in cell
proliferation and cell migration via chromatin level regulation.
Neuroblastoma Associated Transcript-1 Expression
Is Critical for Neuronal Differentiation of
Neuroblastoma Cells
As mentioned earlier in Figure 5H, neuronal processes are
among the top biological processes that were perturbed uponA as a Prognostic Marker for Neuroblastoma
stoma tumors (cohort-I). The expression level of the RNA is presented after
e p value is presented as obtained from Welsh two sample t test (two-sided).
rs (cohort-II) in relation to risk groups and International Neuroblastoma Staging
ltiple comparison test (C).
rt-I and -II. The graphs depict p values as obtained from the Log-rank (Mantel-
groups.
survival status of the patient. Survival status of patients is presented in different
[NED]).
value of NBAT-1 expression with established prognostic markers in cohort-II.
See also Figure S3.
.
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Figure 4. Risk Allele and DNA Methylation Contribute to Neuroblastoma Associated Transcript-1 Differential Expression
(A) Differential expression of NBAT-1 in high-risk tumors with A/A, A/G, or G/G genotype at the SNP: rs6939340. The NBAT-1 expression was calculated as per
Figure 3A.
(B) Allelic status at SNP: rs6939340 and NBAT-1 expression in neuroblastoma cell lines.
(C) Relative luciferase activity of the transfected 500 bp fragments with A/A or G/G genotypes. The luciferase activity values are presented as enrichment over the
pGL3 promoter vector luminescence values.
(D) Screenshot of theNBAT-1 locus showing the position of the disease associated SNP, and ChIA-PET tags showing long range regulatory interactions between
the SNP and NBAT-1 promoter. Below the physical maps, the 3C experiment shows the relative cross-linking frequency between the NBAT-1 promoter and the
regulatory region containing the SNP in SH-SY5Y and SK-N-FI cell lines. Locations of the primers used in the 3C experiment are shown as solid black lines.
(E) ChIP was performed on the cell lines SH-SY5Y (with A/A genotype) and SK-N-FI (with G/G genotype) with antibodies to enhancer-specific histone marks
H3K27ac and H3K4me1. The relative enrichment of the histone modifications are presented after normalizing to corresponding background immunoglobulin G
(IgG) values from two independent biological experiments. The region where primers were designed for quantifying histone modifications is depicted as dashed
line in Figure 4D.
(F) Average methylation (%) levels of the five analyzed CpGs in the NBAT-1 upstream region analyzed by pyrosequencing. The boxplots represent methylation
status in high-risk (n = 13) and low-risk (n = 13) neuroblastoma patients. Physical map depicts the CpGs chosen for methylation analysis and are marked as 1 to 5
in relation to transcription start site (TSS). The p value is presented as obtained from student’s t test.
(G) Activation of NBAT-1 upon DAC treatment of the SK-N-AS cell line with lower NBAT-1 expression. NBAT-1 expression levels in control and DAC treated cells
were normalized to GAPDH. The data represents values obtained from three independent biological experiments.
For (A)–(G), values represent mean ±SD. *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S4.
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Long Noncoding RNAs in Neuroblastoma PathogenesisNBAT-1 knockdown. To investigate the functional role of
NBAT-1 in neuronal differentiation, we utilized SH-SY5Y cells’
ability to differentiate into neurons upon retinoic acid (RA) treat-Canment. Analysis of NBAT-1 expression during the course of
neuronal differentiation after the treatment of the SH-SY5Y cells
with RA for up to 10 days revealed a significant increase in thecer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Inc. 729
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Long Noncoding RNAs in Neuroblastoma Pathogenesisexpression of NBAT-1 (Figure 7A). Downregulation of NBAT-1 in
SH-SY5Y cells resulted in the impairment of the neuronal differ-
entiation process, as these cells showed loss of expression of
neuronal markers (TH, TAU, MAPK, and NSE) and impaired neu-
rite outgrowth, a characteristic feature of neuronal differentiation
(Figures 7A–7C and S6A–S6C). In order to gain further insights
into the functional role of NBAT-1 in the neuronal differentiation,
total RNA from Cntrl-sh and NBAT1-sh cells, treated with RA for
0, 4, and 7 days, was sequenced. Expected expression patterns
of known neuronal markers were found in the RA treated Cntrl-sh
cells (Figures S6D–S6G). We observed 136 differentially ex-
pressed protein-coding genes between D0, D4, and D7 RA
treated Cntrl-sh cells (Figure S6D), whereas in the case of RA
treated NBAT1-sh cells, only 78 protein-coding genes were
differentially expressed (2-fold; FDR < 0.05) (data not shown).
Gene ontology (GO) analysis of the 136 genes from RA treated
Cntrl-sh cells revealed enrichment of major neuronal processes
such as neuronal differentiation, axonogenesis, neurogenesis,
etc. No such significant enrichment of neuronal processes was
found with NBAT1-sh cells (Figure 7D), again indicating that
NBAT-1 plays an important role in neuronal differentiation.
To obtain further insights into NBAT-1 mediated neuronal
differentiation, we chose to stably overexpress NBAT-1 in the
SK-N-AS and SK-N-BE(2) cell lines. NBAT-1 overexpression
induced neuronal differentiation of both cell lines, underscoring
the importance of NBAT-1 in neuronal differentiation (Figures
S6H–S6O).
In order to identify genes/networks perturbed in the NBAT1-sh
cells during RA induced neural differentiation, we have clustered
the differentially expressed genes (1,956 genes) between Cntrl-
sh and NBAT1-sh cells at D0, D4, and D7 (Figures 7E and 7F).
The clustering resulted in five gene clusters with distinct expres-
sion patterns. Interestingly, the cluster IV genes (455 genes) with
reduced expression levels at D4 and D7 showed significant
enrichment for biological processes such as neuron differentia-
tion, neurogenesis, axonogenesis, and nervous system develop-
ment (Figure 7G; Table S8). We validated the expression of some
of the key neuronal genes representing cluster IV using qRT-PCR
(Figure 7H). We next investigated whether the NBAT-1/EZH2Figure 5. Downregulation of Neuroblastoma Associated Transcript-1 L
(A) (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT) assay de
with two siRNAs (si-A and si-C) and a nontarget control (Cntrl-si) in SH-SY5Y ce
(B) Transwell Matrigel invasion assay showing percent increase in the invasion
transduced with control sh-RNA (Cntrl-sh).
(C–E) Subcutaneous injections were performed in nudemice to develop mouse xe
NBAT-1 depleted cells resulted in increase in tumor size up to 29 days. Represen
injected with NBAT1-sh cells, but not with Cntrl-sh cells.
(F) Representative sections of tumors stained with H&E and Ki67. Increased Ki67
(G) Graph representing increased proliferative cells stained with Ki67 in NBAT1-s
(H) GO analysis of the differentially expressed protein coding genes between Cn
(I) Heatmap showing changes in expression of genes involved in cell proliferation a
cells.
(J) Gene network analysis using Cytoscape shows interactions of the differentia
migration.
(K) qRT-PCR validation of some of the key genes implicated in cell proliferation and
(L) Table shows the list of 45 genes (out of 1,348 differentially expressed genes
between the R2 database; Versteeg dataset from R2 database (http://r2.amc.nl)
(M) MTT assay depicting the changes in viable cells post 48 hr of knockdown of
(N) Transwell Matrigel invasion assay showing percent decrease in the invasion o
For (A), (B), (D), (E), (G), (K), (M), and (N), values represent mean ±SD. *p < 0.05 a
Canfunctional interaction has any role in neuronal differentiation.
Although a significant overlap was found between the cluster
IV genes and the EZH2 deregulated gene data set, there was a
significant difference in the pattern of expression among the
overlapped genes. In the NBAT-1 gene data set, 63% of the
overlapped genes show downregulation, whereas in the EZH2
data set, 71% of the overlapped genes show increased ex-
pression (Figure S6P). More importantly, none of the cluster
IV genes showed overlap with H3K27me3 ChIP followed by
DNA sequencing (seq)-peaks. These observations indicate
that NBAT-1 and EZH2 play critical roles in neurogenesis, but
their functional interaction has no role in the regulation of
neurogenesis.
We next sought to address the reasons underlying the down-
regulation of neuronal lineage-specific genes upon NBAT-1
downregulation. A neuron restrictive silencing factor NRSF/
REST, which represses the expression of neuronal genes in
nonneuronal tissues and embryonic stem cells, was upregu-
lated upon NBAT-1 downregulation (Figures 8A and S7A).
Also, an increased expression of NRSF/REST was found in
MNA tumors relative to non-MNA tumors in the R2 data set (Fig-
ure S7B). Interestingly, a significant proportion of NBAT-1
affected neuronal genes (cluster IV) have NRSF/REST binding
sites, characterized in a publically available ChIP-seq data set
(Figure 8B; Table S9) (Wang et al., 2012b), indicating that
NBAT-1 may control neural commitment via repressing the
NRSF/REST pathway. Consistent with this notion, upregulation
of several neuronal lineage-specific genes and restoration of the
neuronal phenotype was observed when NRSF/REST was
downregulated in the NBAT1-sh cells (Figures 8C, 8D, and
S7C). It is also important to note that many REST targets such
as KLF7, SYT2, and PIPOX are expressed at significantly lower
levels in high-risk patients (Versteeg dataset from R2 database
http://r2.amc.nl) (Figure S7D) and showed relaxation of their
silencing upon NRSF/REST knockdown in the NBAT-1 downre-
gulated SH-SY5Y cells (Figure 8E). Collectively, these observa-
tions indicate that the regulation of key genes required for
proper neuronal differentiation occurs via a NBAT-1 regulated
NRSF/REST pathway.eads to Increased Cell Proliferation and Invasion
picting the changes in viable cells post 48 hr siRNA knockdown ofNBAT-1 RNA
lls.
of the NBAT-1 shRNA transduced cells (NBAT1-sh) compared to the cells
nografts with either Cntrl-sh (n = 9) or NBAT1-sh (n = 9) cells. (D) Injection of the
tative picture (C) and graph (E) showing increased tumor volume in the mouse
immunostaining in NBAT1-sh xenografts is visible.
h xenografts as compared to Cntrl-sh.
trl-sh and NBAT1-sh cells.
nd cell migration in theNBAT-1 downregulated cells as compared to the control
lly expressed genes (with 3-fold difference) implicated in cell proliferation and
migration uponNBAT-1 (upper panel) and EZH2 downregulation (lower panel).
between NBAT1-sh and Cntrl-sh cells), showing similar expression patterns
(Molenaar et al., 2012) and the NBAT-1 downregulated cells.
VCAN, SOX9, or OSMR transcripts in NBAT1-sh cells using siRNAs.
f the NBAT1-sh cells transfected with siRNAs against VCAN, SOX9, or OSMR.
nd **p < 0.01. See also Figure S5 and Table S6.
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Figure 6. Neuroblastoma Associated Transcript-1 Acts as a Tumor Suppressor via Interacting with EZH2
(A) RIP assay showing the interaction between NBAT-1 RNA and EZH2. Graph shows the fold enrichment of EZH2 bound NBAT-1 RNA over IgG. U1 snRNA
enrichment was taken as negative control.
(B) Heatmap showing common expression changes upon downregulation of NBAT-1 and EZH2.
(C) Scatter plot showing significant correlation between the expression changes in theNBAT-1 andEZH2 downregulated cells (Pearson correlation coefficient; r =
0.67). Genes enriched with H3K27me3 mark at their promoters (±3 kb from TSS) are highlighted (Egan et al., 2013).
(D) Pie chart showing the number of NBAT-1/EZH2 target genes implicated in cell proliferation and migration enriched with H3K27me3 marks.
(E) NBAT-1/EZH2 target genes showing changes in H2K27me3 levels upon NBAT-1 downregulation as measured using ChIP assay. The relative enrichment of
H3K27me3 over input at the target gene promoters is presented.
For (A) and (E), values represent mean ±SD. See also Table S7.
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In this study, we characterized differentially expressed lncRNAs
between low- and high-risk neuroblastomas. We identified 24
lncRNAs, which can distinguish the high-risk tumors from low-
risk tumors. These noncoding signatures could serve as comple-
mentary information, alongside with established biomarkers
such as amplification of theMYCN gene and heterozygous dele-
tion of the 11q arm, for efficient stratification of the disease.
In addition, this study also identified lncRNAs that map to com-
monly occurring nonrandom chromosome alterations, MNA, 1p
deletion, and 11q deletion. LncRNAs that map to the amplicons
on 2p associated with MNA and to the 11q deletion region could
act as oncogene and tumor suppressor genes, respectively.
Validation of their expression in an extended series of tumors
suggests potential roles in the pathogenesis ofMNA and 11q- tu-
mors. Further characterization of the mode of action of these
lncRNA would be needed to explain how their aberrant expres-
sion, due to genomic imbalances, might contribute to the patho-
genesis of specific subtypes of the disease.732 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier IncThe current investigation implicates NBAT-1 expression as an
independent prognostic marker in patients with neuroblastoma.
This RNA is expressed at lower levels in high-risk (both 11q- and
MNA) tumors, and its lower expression could serve as a risk fac-
tor to predict adverse outcome among neuroblastoma patients.
Our study suggests that multiple factors contribute to differential
expression of NBAT-1 among the neuroblastoma subtypes. Hy-
permethylation at the NBAT-1 promoter in high-risk patients in-
dicates that DNA methylation is one of the primary mechanisms
that contribute to NBAT-1 repression in these patients. In addi-
tion, we show that there is a functional correlation between
NBAT-1 expression and the previously identified high-risk asso-
ciated SNP (rs6939340) on 6p22 in intron 2 of the NBAT-1 gene
(Maris et al., 2008). Thus, our study demonstrates that both ge-
netic and epigenetic changes underlie the differential expression
of NBAT-1 in neuroblastoma subtypes.
Our cell culture and mouse xenograft models clearly demon-
strate that NBAT-1 has tumor suppressor properties, such as
anticell proliferation and anticell invasion. In this context,
detailed investigation of the NBAT-1 target genes revealed an.
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Long Noncoding RNAs in Neuroblastoma Pathogenesisinterconnected network of affected genes (Figure 5J). Some of
the genes present in this network (SOX9, VCAN, and OSMR)
have been shown to contribute to tumor progression in several
cancer types. Loss of proliferative and invasive properties of
NBAT1-sh cells upon downregulation of SOX9, OSMR, and
VCAN indicates thatNBAT-1 controls tumor progression by sup-
pressing these genes. The higher expression of SOX9 and VCAN
genes in high-risk tumors compared to low-risk neuroblastoma
tumors in our and R2 data sets further supports their functional
role in tumor progression in high-risk neuroblastomas. Impor-
tantly, SOX9 maps to 17q24, and the gain of 17q is the most
frequent abnormality in neuroblastoma tumors with poor prog-
nosis (Care´n et al., 2010; Lastowska et al., 2001). Collectively,
these observations further emphasize the functional role of
SOX9 in neuroblastoma tumor progression.
Our data demonstrates that NBAT-1 epigenetically controls
the expression of target genes involved in cell proliferation and
cell invasion by interacting with EZH2. Upregulation of NBAT-1
target genes implicated in cell proliferation and invasion in both
EZH2 and NBAT-1 knockdown cells and loss of H3K27me3
from their promoter regions, suggest that a NBAT-1/EZH2 func-
tional interaction may repress these genes in low-risk patients
via chromatin level regulation. The decreased NBAT-1 expres-
sion in high-risk tumors could be the underlying cause for the
increased cell proliferation and cell invasion in these tumors by
activating SOX9 and VCAN dependent pathways. However,
increased EZH2 expression has been observed in high-risk neu-
roblastoma tumors, and this has been functionally linked to
increased cell proliferation (Wang et al., 2012a). Considering
that NBAT-1 is expressed at low level in high-risk tumors, we
are tempted to speculate that NBAT-1 acts as a scaffold for
the EZH2 recruitment, and that EZH2 is no longer recruited to
repress NBAT-1/EZH2 target genes in the absence of NBAT-1
expression, thus increasing the expression of genes involved in
tumor progression (Figure 8F). Consistent with this idea, overex-
pression of EZH2 in NBAT1-sh cells had no significant effect on
the expression of SOX9, OSMR, and VCAN genes (data not
shown).
Another interesting aspect of the current study is NBAT-1’s
functional role in RA induced neuronal differentiation. Impaired
neuronal differentiation of neuronal precursor cells is one of the
characteristic features of high-risk neuroblastomas (Nakaga-
wara et al., 1993). We demonstrate that the inability of NBAT1-
sh cells to achieve neuronal differentiation is due to upregulation
of the NRSF/REST pathway and consequent downregulation of
some of its key neuronal-specific genes (Figure 8F). Further-Figure 7. Neuroblastoma Associated Transcript-1 Expression Is Critic
(A) qRT-PCR measurement of NBAT-1 expression during RA induced neuronal
lentiviral particles.
(B) Immunostaining of the Cntrl-sh and NBAT1-sh SH-SY5Y cells 5 days after R
TUBULIN immunostaining is used as a control.
(C) Percent of neurite outgrowths observed in the Cntrl-sh and NBAT1-sh cells s
(D) GO analysis of the differentially expressed genes in the Cntrl-sh (136 genes)
(E) Heatmap showing clustering of all genes that displayed a 3-fold or greater diffe
sh cells at days 0, 4, and 7 of RA treatment. Cluster IV genes were not induced d
(F) Network analysis on the cluster IV genes generated using Cytoscape.
(G) GO analysis of the cluster IV revealed enrichment of biological processes rela
(H) qRT-PCR validation of some of the cluster IV genes in the NBAT1-sh cells po
For (A), (C), and (H), values represent mean ±SD. See also Figure S6 and Table S
734 Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Incmore, the restoration of neuronal phenotype and relaxation of
silencing of some of the key neuronal-specific genes upon
NRSF/REST downregulation in the NBAT1-sh cells, suggests
thatNBAT-1 controls the neuronal lineage commitment via regu-
lating NRSF/REST activity. Increased expression of NRSF/REST
in MNA tumors relative to non-MNA tumors in the Versteeg data-
set from R2 database (http://r2.amc.nl), and the recent sugges-
tion that HOXC9 induced regression of neuroblastoma tumors
involves downregulation of NRSF/REST (Kocak et al., 2013) pro-
vides an explanation for the impairment of differentiation of
neuronal precursor cells in high-risk patients. In addition, upre-
gulation of NRSF/REST in medulloblastoma patients has also
been shown to affect the differentiation of neural stem/progeni-
tors into neurons (Su et al., 2006). These observations clearly
indicate that NBAT-1 mediated NRSF/REST suppression could
be a critical pathway regulating the neuronal fate commitment.
Disturbance in this pathway could be one of the underlying
causes for neural related cancers that are a result of impairment
of neuronal differentiation. The RNA-sequencing data ofNBAT-1
and EZH2 downregulated cells indicate that the NBAT-1/EZH2
functional interaction does not have any functional role in the
neural lineage commitment. Though EZH2 and NBAT-1 have
critical roles in neurogenesis, they operate by different path-
ways, and this observation is consistent with the fact that down-
regulation of EZH2 promotes neurogenesis (Wang et al., 2012a),
while that of NBAT-1 impairs neuronal differentiation.
Taken together, these observations reveal that NBAT-1 is a
biomarker for risk assessment for neuroblastoma tumors. Addi-
tionally, the role of NBAT-1 in cell proliferation, invasion, and
neuronal differentiation elucidates mechanisms and gene net-
works involved in neuroblastoma tumor development and pro-
gression. Both NBAT-1 and its downstream effectors (SOX9
andNRSF/REST) could serve as potential targets for drug devel-
opment and options for neuroblastoma clinical treatment.EXPERIMENTAL PROCEDURES
Patient and Tumor Material
Neuroblastoma primary tumors were obtained at surgery, snap frozen, and
stored at 70C until analysis. For RNA sequencing, a set of 15 tumors were
selected: three clinical low-risk (Cohn et al., 2009) with a numerical only geno-
type (Care´n et al., 2010), and 12 high-risk tumors with MYCN-amplification
(n = 6) and 11q deletion (n = 6). In cohort I, a total of 106 Swedish and two
German patients were included according to ethical permit number (Dnr
2011/354), it was approved by Regional Ethical Review Board, Uppsala Uni-
versity, Uppsala, and informed consent from the legal guardian was secured.
In cohort II, RNA-seq data from 498 patients was used. These patients wereal for Neuronal Differentiation
differentiation of the SH-SY5Y cells transduced with Cntrl-sh and NBAT1-sh
A treatment using the antibodies specific to neuronal markers TAU and TH.
tained with TAU and TH.
or NBAT1-sh (78 genes) cells treated with RA for 0, 4, and 7 days.
rence in expression levels betweenNBAT-1 depleted SH-SY5Y cells and Cntrl-
uring differentiation, upon loss of NBAT-1.
ted to neuronal development and differentiation. nd, neuronal differentiation.
st RA induced differentiation.
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Figure 8. Neuroblastoma Associated Transcript-1 Regulates Neural Lineage Commitment through the Suppression of NRSF/REST
(A) qRT-PCR measurement of NRSF/REST expression during RA induced differentiation of NBAT1-sh and Cntrl-sh cells.
(B) Venn-diagram showing number of cluster IV genes (Figures 7E and 7F) with NRSF/REST binding sites (Wang et al., 2012b).
(C)NRSF/REST downregulation rescues neuronal phenotype in NBAT1-sh cells. Bright field microscopy images (203) of SH-SY5Y (NBAT1-sh) cells, transfected
with REST siRNA (REST-si) or Cntrl siRNA (Cntrl-si) followed by 4 days of RA treatment.
(D) Immunostaining of the Cntrl-sh and NBAT1-sh cells, treated with Cntrl-si or REST-si followed by 4 days of RA treatment, using the antibodies specific to
neuronal marker TAU.
(E) qRT-PCR measurement of relaxation of NRSF/REST target genes upon downregulation of REST in the NBAT1-sh cells.
(F) Model explaining the tumor suppressor and neuronal differentiation properties of NBAT-1. NBAT-1 functional interaction with EZH2, a member of PRC2
complex, controls tumor progression by suppressing protumor genes such as SOX9, VCAN, and OSMR via regulating chromatin structure. On the other hand,
NBAT-1 promotes neuronal lineage commitment by suppressing NRSF/REST by interacting with an unknown neuronal-linage-specific transcriptional repressor.
The NBAT-1/EZH2 interaction has no functional role in the repression of NRSF/REST.
For (A) and (E), values represent mean ±SD. See also Figure S7 and Table S9.
Cancer Cell
Long Noncoding RNAs in Neuroblastoma Pathogenesis
Cancer Cell 26, 722–737, November 10, 2014 ª2014 Elsevier Inc. 735
Cancer Cell
Long Noncoding RNAs in Neuroblastoma Pathogenesisregistered in respective clinical trials with informed consent (NB2004, 04-049;
NB97, 9764; ethical committee of the Medical Faculty of the University of
Cologne). Details of two tumor cohorts, Array-CGH profiles of the sequenced
tumors, and other experimental procedures are described in detail in Supple-
mental Experimental Procedures.
Mouse Xenograft Tumor Model and Histology
33106 cells infected with either Cntrl-sh or NBAT1-sh (n = 9) were subcutane-
ously injected on the dorsal back region of 5- to 6-week-old Bagg Albino
(inbred research mouse strain) nude male mice (Charles River Laboratories)
as described earlier (Nallapalli et al., 2012). Tumors were harvested and half
of each tumor was frozen in liquid nitrogen and stored in 80C, whereas
the other half was fixed in 4% paraformaldehyde for immunostaining. All the
mouse experiments were approved by Animal Ethical Review Board, Univer-
sity of Gothenburg, Gothenburg, Sweden (Ethical permit number-62/14).
Paraffin-embedded tumor tissues were analyzed by hematoxylin and eosin
staining (H&E). Immunostaining with Ki67 (Thermo Scientific) antibody was
performed to detect the number of replicating cells as described earlier (Nal-
lapalli et al., 2012). Ki67 staining positivity was quantified in three different
high power fields of each section, and the mean ±SD values were given.
RNA Isolation and Library Preparation
Tumors from neuroblastoma patients were cut on dry ice. Total RNA was iso-
lated from the tumors using thePromega Total RNA IsolationKit (Promega). Iso-
lated RNA was ribo-depleted using the Ribominus Eukaryotic Kit (Invitrogen)
according to the manufacturer’s instructions. Ribo-depleted RNA was used
to prepare a whole transcriptome library (Applied Biosystems) as per the man-
ufacturer’s protocol. Quality, size, and concentration of the RNA during library
preparation were analyzed using Bioanalyser 2100 (RNA Pico Kit, Agilent). Final
amplified cDNA library was analyzed using DNA Hypersensitive Kit (Agilent).
Pyrosequencing
Pyrosequencing was performed to analyze the methylation levels at five CpGs
sites (labeled in Figure 4F) at the NBAT-1 promoter. Genomic DNA from 13 tu-
mors, each representing low-risk and high-risk tumors, were bisulphite con-
verted and analyzed as described earlier (Martinelli et al., 2013). The primers
used for pyrosequencing analysis are mentioned in the Supplemental Experi-
mental Procedures.
ACCESSION NUMBERS
The RNA sequencing files (FASTQ) have been deposited in European Nucleo-
tide Archive (ENA) with study accession number: PRJEB6912 (http://www.ebi.
ac.uk/ena/data/view/PRJEB6912).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and nine tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.09.014.
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